Inventor · disambiguated record
Edward Wancewicz
Also filed as: WANCEWICZ EDWARD
14 granted patents·9 pending applications·239 citations·filing 2000–2015
94Inventor score
Top patents by PatentIndex Score
23 records- 0198US9617540B2Compounds and methods for modulating gene expressionIONIS PHARMACEUTICALS INC·Filed 2015·Granted Apr 11, 2017·26 cites·20 claims
- 0298US9045754B2Short antisense compounds with gapmer configurationBHANOT SANJAY·Filed 2007·Granted Jun 2, 2015·56 cites·44 claims
- 0397US8143230B2Compounds and methods for modulating expression of PCSK9BHANOT SANJAY·Filed 2007·Granted Mar 27, 2012·44 cites·46 claims
- 0495US8188059B2Compounds and methods for modulating expression of GCGRBHANOT SANJAY·Filed 2007·Granted May 29, 2012·22 cites·36 claims
- 0593US8586554B2Compounds and methods for modulating expression of PTP1BBHANOT SANJAY·Filed 2007·Granted Nov 19, 2013·13 cites·45 claims
- 0693US6331399B1Antisense inhibition of tert expressionISIS PHARMACEUTICALS INC·Filed 2000·Granted Dec 18, 2001·42 cites·32 claims
- 0788US8372967B2Compounds and methods for modulating expression of GCCRISIS PHARMACEUTICALS INC·Filed 2007·Granted Feb 12, 2013·5 cites·75 claims
- 0886US8673871B2Compounds and methods for modulating expression ApoBBHANOT SANJAY·Filed 2007·Granted Mar 18, 2014·4 cites·19 claims
- 0983US8362232B2Compounds and methods for modulating expression of SGLT2ISIS PHARMACEUTICALS INC·Filed 2010·Granted Jan 29, 2013·3 cites·46 claims
- 1081US6492171B2Antisense modulation of TERT expressionISIS PHARMACEUTICALS INC·Filed 2000·Granted Dec 10, 2002·7 cites·32 claims
- 1179US8084436B2Modulation of SGLT2 expressionFREIER SUSAN M·Filed 2008·Granted Dec 27, 2011·3 cites·54 claims
- 1277US8969316B2Compounds and methods for modulating expression of DGAT2ISIS PHARMACEUTICALS INC·Filed 2012·Granted Mar 3, 2015·1 cites·20 claims
- 1376US6607915B1Antisense inhibition of E2A-Pbx1 expressionISIS PHARMACEUTICALS INC·Filed 2000·Granted Aug 19, 2003·4 cites·25 claims
- 1471US8258105B2Antisense oligonucleotides optimized for kidney targetingSIWKOWSKI ANDREW M·Filed 2004·Granted Sep 4, 2012·9 cites·25 claims
- 1568US2015057329A1Compounds and methods for modulating expression apobISIS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1663US2012208864A1Compounds and methods for modulating expression of gcgrBHANOT SANJAY·Filed 2012·Application pending·0 cites
- 1757US2005222073A1Antisense modulation of thyroid hormone receptor interactor 6 expressionBENNETT C F·Filed 2005·Application pending·0 cites
- 1856US2005137160A1Antisense modulation of cholesteryl ester transfer protein expressionISIS PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 1954US2005191653A1Modulation of SGLT2 expressionFiled 2004·Application pending·0 cites
- 2054US2012022133A1Antisense modulation of cholesteryl ester transfer protein expressionCROOKE ROSANNE M·Filed 2011·Application pending·0 cites
- 2151US2003092647A1Antisense modulation of cholesteryl ester transfer protein expressionFiled 2001·Application pending·0 cites
- 2250US2012196921A1Modulation of sglt-2 expressionFREIER SUSAN M·Filed 2011·Application pending·0 cites
- 2348US2007299028A1Backbone modifications to modulate oligonucleotide targeting in vivoSIWKOWSKI ANDREW M·Filed 2007·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →